The Amplatzer Piccolo Occluder received FDA approval and CE Mark in 2019. "We designed the Amplatzer Piccolo Delivery System based on feedback from leading physicians across the world to make PDA ...

- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation - New delivery ...

PARIS, France—Left atrial appendage (LAA) occlusion with the Amplatzer Amulet (Abbott) reduces the risk of ischemic stroke in real-world use through 2 years, for the most part without the need for ...

Abbott has received a new, broad approval from the FDA for its tiny heart plug implant to help cut down the risk of stroke among people with atrial fibrillation, the most common cardiac arrhythmia.

Left atrial appendage (LAA) closure using the Amplatzer cardiac plug is associated with lower than expected risks of systemic thromboembolism and major bleeding in patients with nonvalvular A-fib, ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...

A PDA requiring treatment is present in approximately 20% of premature infants 1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug ...

ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...